Meropenem Plasma and Interstitial Soft Tissue Concentrations in Obese and Nonobese Patients-A Controlled Clinical Trial.
Philipp SimonDavid PetroffDavid BusseJana HeyneFelix GirrbachArne DietrichAlexander KratzerMarkus ZeitlingerCharlotte KloftFrieder KeesHermann WriggeChristoph DornPublished in: Antibiotics (Basel, Switzerland) (2020)
In morbidly obese patients, meropenem has lower maximum concentrations and higher volumes of distribution. However, due to the slightly longer half-life, obesity has no influence on the T > MIC, so dose adjustments for obesity seem unnecessary.
Keyphrases
- obese patients
- bariatric surgery
- weight loss
- metabolic syndrome
- roux en y gastric bypass
- gastric bypass
- clinical trial
- type diabetes
- insulin resistance
- soft tissue
- end stage renal disease
- weight gain
- newly diagnosed
- ejection fraction
- high fat diet induced
- peritoneal dialysis
- gram negative
- body mass index
- patient reported